MammaPrint is the first and only FDA-cleared IVDMIA breast cancer recurrence assay. The unique 70-gene signature of MammaPrint provides clinicians with a second generation tool that stratifies a much broader range of early stage breast cancer patients into either a low risk vs. high risk of distant cancer recurrence following surgery. This test goes well beyond the first generation 21-gene test by accurately providing guidance for patients who have the more challenging estrogen receptor low or negative and Her-2 positive patients. Furthermore, MammaPrint evaluates all of the critical molecular pathways involved in the formation of potentially lethal metastasis as opposed the more limited first generation tests. It is equally accurate in formalin fixed-parrafin embedded tissues as it was originally in fresh and frozen tissue. This provides equal access for breast surgeons as well as medical oncologists to offer this critical analysis to patients.
Agendia is a leading molecular diagnostic company that develops and markets FFPE-based genomic diagnostic products. Agendia's breast cancer Symphony™ suite was developed using unbiased gene selection, analyzing the complete human genome, ensuring 100% definitive results for cancer patients. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo, hormonal, or combination therapy, and which patients do not require these treatments and can instead be treated with other less arduous and less costly methods.
In addition to the Symphony suite of tests, Agendia has a rich pipeline of genomic products in development. The Company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and M
Copyright©2012 PR Newswire.
All rights reserved